Counteracting aldosterone in cardiorenal disease in type 2 diabetes through finerenone administration

被引：0
|
作者：
Ruilope, L. M. [1 ,2 ,3 ]
Ruiz-Hurtado, G. [1 ,2 ]
机构：
[1] Hosp Univ 12 Octubre, Inst Res I 12, Cardiorenal Translat Lab, Madrid, Spain
[2] Hosp Univ 12 Octubre, CIBER CV, Madrid, Spain
[3] European Univ Madrid, Sch Doctoral Studies & Res, Madrid, Spain
来源：
HIPERTENSION Y RIESGO VASCULAR | 2023年 / 40卷 / 02期
关键词：
CHRONIC KIDNEY-DISEASE; MINERALOCORTICOID RECEPTOR;
D O I：
10.1016/j.hipert.2022.11.002
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：55 / 57
页数：3
相关论文
共 50 条
  • [21] Cardiorenal Outcomes With Finerenone in Asian Patients With CKD and Type 2 Diabetes: Post Hoc Analysis From FIDELIO-DKD
    Koya, Daisuke
    Anker, Stefan D.
    Ruilope, Luis M.
    Rossing, Peter
    Lee, Byung-Wan
    Lee, Chien-Te
    Liu, Zhi Hong
    Scott, Charlie
    Kolkhof, Peter
    Lawatscheck, Robert
    Wang, Lili
    Joseph, Amer
    Pitt, Bertram
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 678 - 678
  • [22] Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes
    Agarwal, Rajiv
    Ruilope, Luis M.
    Ruiz-Hurtado, Gema
    Haller, Hermann
    Schmieder, Roland E.
    Anker, Stefan D.
    Filippatos, Gerasimos
    Pitt, Bertram
    Rossing, Peter
    Lambelet, Marc
    Nowack, Christina
    Kolkhof, Peter
    Joseph, Amer
    Bakris, George L.
    [J]. JOURNAL OF HYPERTENSION, 2023, 41 (02) : 295 - 302
  • [23] Finerenone (Kerendia) for the Treatment of Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus
    Stewart-Lynch, Autumn
    [J]. AMERICAN FAMILY PHYSICIAN, 2023, 108 (03) : 305 - 306
  • [24] Cardiorenal Effects of Sglt2 Inhibitors and Finerenone in Type 2 Diabetes and Chronic Kidney Disease. Single, Dual or Triple Therapy? A Network Meta-Analysis
    Acevedo, Jesus Diaz
    Lazcano, Greilys
    Soto, Mariana
    Castro, Adela
    Penaherrera, Carlos
    Buitrago, Andres F.
    Narayanankutty, Naveen Punchayil
    Navas, Viviana
    Pino, Jesus E.
    [J]. CIRCULATION, 2022, 146
  • [25] Optimization of potassium management in patients with chronic kidney disease and type 2 diabetes on finerenone
    Ortiz, Alberto
    Arroyo, Roberto Alcazar
    Escribano, Pedro Pablo Casado
    Fernandez-Fernandez, Beatriz
    Deben, Francisco Martinez
    Mediavilla, Juan Diego
    Michan-Dona, Alfredo
    Soler, Maria Jose
    Gorriz, Jose Luis
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2023, 16 (06) : 519 - 531
  • [26] Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis
    Filippatos, Gerasimos
    Anker, Stefan D.
    August, Phyllis
    Coats, Andrew J. S.
    Januzzi, James L.
    Mankovsky, Boris
    Rossing, Peter
    Ruilope, Luis M.
    Pitt, Bertram
    Sarafidis, Pantelis
    Teerlink, John R.
    Kapelios, Chris J.
    Gebel, Martin
    Brinker, Meike
    Joseph, Amer
    Lage, Andrea
    Bakris, George
    Agarwal, Rajiv
    [J]. EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2023, 9 (02) : 183 - 191
  • [27] Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes
    Ashjian, Emily
    Clarke, Megan
    Pogue, Kristen
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2023, 80 (23) : 1708 - 1721
  • [28] The residual cardiorenal risk in type 2 diabetes
    Giugliano, Dario
    Maiorino, Maria Ida
    Bellastella, Giuseppe
    Esposito, Katherine
    [J]. CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
  • [29] Acute Aldosterone Administration Increases Vascular Resistance in Patients with Type 2 Diabetes
    Finsen, Stine Hoyer
    Mortensen, Stefan P.
    [J]. FASEB JOURNAL, 2019, 33
  • [30] The residual cardiorenal risk in type 2 diabetes
    Dario Giugliano
    Maria Ida Maiorino
    Giuseppe Bellastella
    Katherine Esposito
    [J]. Cardiovascular Diabetology, 20
12345